Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly  Settings
SGMO Sangamo Therapeutics, Inc. daily Stock Chart
SGMO [NASD]
Sangamo Therapeutics, Inc.
Healthcare | Biotechnology | USA
financial highlights | statements
Index- P/E- EPS (ttm)-0.89 Insider Own0.20% Shs Outstand109.93M Perf Week-2.51%
Market Cap1.02B Forward P/E- EPS next Y-1.30 Insider Trans-13.73% Shs Float109.93M Perf Month-9.35%
Income-90.30M PEG- EPS next Q-0.36 Inst Own58.10% Short Float14.01% Perf Quarter-4.41%
Sales79.90M P/S12.81 EPS this Y-0.90% Inst Trans2.68% Short Ratio7.88 Perf Half Y-24.06%
Book/sh3.21 P/B2.90 EPS next Y7.60% ROA-15.30% Target Price23.20 Perf Year-40.13%
Cash/sh3.19 P/C2.92 EPS next 5Y- ROE-24.70% 52W Range6.26 - 19.25 Perf YTD-18.90%
Dividend- P/FCF- EPS past 5Y-8.20% ROI-19.60% 52W High-51.64% Beta2.92
Dividend %- Quick Ratio4.00 Sales past 5Y28.50% Gross Margin- 52W Low48.72% ATR0.47
Employees302 Current Ratio4.00 Sales Q/Q-35.70% Oper. Margin- RSI (14)42.08 Volatility3.84% 4.49%
OptionableYes Debt/Eq0.04 EPS Q/Q-76.30% Profit Margin- Rel Volume0.38 Prev Close9.60
ShortableYes LT Debt/Eq0.04 EarningsMay 08 AMC Payout- Avg Volume1.95M Price9.31
Recom2.00 SMA20-2.27% SMA50-13.74% SMA200-20.61% Volume748,410 Change-3.02%
Nov-14-18Downgrade JP Morgan Overweight → Neutral
Nov-09-18Downgrade Guggenheim Buy → Neutral
Oct-10-18Initiated Guggenheim Buy
Jun-20-18Initiated BofA/Merrill Buy $24
Nov-15-17Upgrade Piper Jaffray Neutral → Overweight
Jun-22-17Resumed Jefferies Buy $17
Nov-01-16Downgrade Wedbush Outperform → Neutral $30 → $4
Oct-19-16Downgrade Piper Jaffray Overweight → Neutral
Dec-04-15Initiated Wells Fargo Outperform
Oct-23-15Resumed Jefferies Buy
May-03-13Initiated BioLogic Equity Research Sell
Feb-23-11Reiterated JMP Securities Mkt Outperform $9 → $12
Jul-29-10Reiterated Wedbush Outperform $12 → $13
Oct-19-09Initiated Brean Murray Sell $4
Oct-07-09Reiterated Leerink Swann Outperform $9 → $11
Aug-25-09Reiterated JMP Securities Mkt Outperform $13 → $15
Apr-14-09Downgrade Cantor Fitzgerald Buy → Hold
Feb-23-09Reiterated Leerink Swann Outperform $6 → $9
Feb-05-09Upgrade Merriman Curhan Ford Neutral → Buy
Nov-20-08Reiterated Cantor Fitzgerald Buy $27 → $4
Jun-12-19 09:35PM  Edited Transcript of SGMO earnings conference call or presentation 8-May-19 9:00pm GMT Thomson Reuters StreetEvents
10:30AM  Denali's Hunter Syndrome Candidate Gets Orphan Drug Status Zacks
May-28-19 05:35PM  A hemophilia patient hero at zero, BioMarin to seek FDA OK for gene therapy. But will the effect last? American City Business Journals
May-15-19 04:30PM  Sangamo Therapeutics Announces Presentations At Upcoming Scientific, Medical And Investor Conferences PR Newswire
May-10-19 08:30AM  Sangamo Therapeutics Announces Participation In The Bank Of America Merrill Lynch 2019 Health Care Conference PR Newswire
May-09-19 01:23PM  Sangamo Biosciences Inc (SGMO) Q1 2019 Earnings Call Transcript Motley Fool -14.77%
11:21AM  Here's Why Sangamo Therapeutics Fell as Much as 13.6% Today Motley Fool
May-08-19 10:15PM  What You Need to Know About Sangamo Therapeutics' Q1 Earnings Results Motley Fool
06:15PM  Sangamo Therapeutics (SGMO) Reports Q1 Loss, Lags Revenue Estimates Zacks
05:01PM  Sangamo: 1Q Earnings Snapshot Associated Press
04:01PM  Sangamo Therapeutics Reports First Quarter 2019 Financial Results PR Newswire
03:00PM  Sangamo Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
May-05-19 09:10AM  If You Had Bought Sangamo Therapeutics (NASDAQ:SGMO) Stock Three Years Ago, You Could Pocket A 93% Gain Today Simply Wall St.
May-02-19 02:56PM  Heres What Hedge Funds Think About Sangamo Therapeutics, Inc. (SGMO) Insider Monkey
May-01-19 04:01PM  Sangamo Therapeutics Announces First Quarter 2019 Conference Call And Webcast PR Newswire
Apr-28-19 11:52PM  Sangamo (SGMO) Q1 Earnings: What's in Store for the Stock? Zacks
Apr-15-19 04:01PM  Sangamo Therapeutics Announces Presentations At 2019 Annual Meeting Of The American Society Of Gene & Cell Therapy PR Newswire
Apr-08-19 04:01PM  Sangamo Therapeutics Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares PR Newswire
Apr-05-19 06:00AM  Sangamo- Biotech "Fires on All Cylinders" MoneyShow
Apr-04-19 08:00AM  Sangamo Therapeutics Announces Pricing of Public Offering of Common Stock PR Newswire -6.83%
07:58AM  The Daily Biotech Pulse: Recro Restructures, Biotechs Raise Proceeds In Droves, Silk Road, NGM Biopharma To Debut Benzinga
Apr-03-19 04:01PM  Sangamo Therapeutics Announces Proposed Public Offering of Common Stock PR Newswire +6.02%
10:15AM  Sangamo Rises on Positive Phase I/II Hemophilia Study Data Zacks
09:15AM  Stocks Hold Onto Gains in Quiet Session Zacks
08:13AM  Does Sangamo Have the Best Gene Therapy Program Now? Motley Fool
07:37AM  3 Big Stock Charts for Wednesday: Twitter, Western Union and Wynn Resorts InvestorPlace
Apr-02-19 04:30PM  Why Delta Air Lines, Sangamo Therapeutics, and Grayscale Bitcoin Trust Jumped Today Motley Fool +28.96%
04:17PM  Gene-Focused Biotechs Pop After Pfizer Partner Scores In Hemophilia A Investor's Business Daily
12:47PM  Sangamo Soars Amid Multiple Development Pipeline Updates Benzinga
12:43PM  Sangamo Therapeutics Bull Gap Fuels Hot Options Trading Schaeffer's Investment Research
11:53AM  Sangamo Therapeutics News: Why SGMO Stock Is Soaring Today InvestorPlace
11:33AM  Why Sangamo Therapeutics Stock Is Soaring Today Motley Fool
09:55AM  Sangamo Stock Soars on Positive Hemophilia Treatment Trial TheStreet.com
08:10AM  Sangamo's stock soars after upbeat trial data for hemophilia treatment MarketWatch
07:00AM  Sangamo Provides Clinical Development Update Including Early Phase 1/2 Beta Thalassemia Gene-edited Cell Therapy Data PR Newswire
07:00AM  Sangamo Announces Agreement Securing Access To Large-Scale, Commercial-Grade Manufacturing Capacity At Brammer Bio PR Newswire
07:00AM  Sangamo and Pfizer Announce Phase 1/2 Interim Data For Investigational Hemophilia A Gene Therapy PR Newswire
07:00AM  Sangamo and Pfizer Announce Phase 1/2 Interim Data for Investigational Hemophilia A Gene Therapy Business Wire
Apr-01-19 04:43PM  Sangamo Therapeutics To Host April 2, 2019 Conference Call To Provide Clinical Update PR Newswire
Mar-29-19 07:00AM  Sangamo Therapeutics Presents New Preclinical Data Demonstrating Significant Reduction In Tau Expression With Gene Regulation Technology PR Newswire
Mar-28-19 08:19AM  Better Buy: CRISPR Therapeutics vs. Sangamo Therapeutics Motley Fool
Mar-26-19 07:16AM  Better Buy: Editas Medicine vs. Sangamo Therapeutics Motley Fool
Mar-25-19 09:15AM  S&P Holds Onto 2800 Despite Sharp Selloff Zacks
07:30AM  Report: Exploring Fundamental Drivers Behind M.D.C., salesforce.com, inc, Citrix, Match Group, Sangamo Therapeutics, and Popular New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Mar-19-19 01:42PM  Edited Transcript of SGMO earnings conference call or presentation 28-Feb-19 10:00pm GMT Thomson Reuters StreetEvents
Mar-12-19 01:08PM  What Type Of Shareholder Owns Sangamo Therapeutics, Inc.s (NASDAQ:SGMO)? Simply Wall St.
12:23PM  Signal Says Sell This Biotech Stock Schaeffer's Investment Research
07:00AM  Sangamo Therapeutics Appoints Jason Fontenot, Ph.D., As Senior Vice President, Cell Therapy PR Newswire
Mar-08-19 05:00AM  Sangamo Therapeutics Announces Publication Of Data Demonstrating New Zinc Finger Nuclease Architectures Enabling High-Precision Genome Editing PR Newswire
Mar-07-19 02:47PM  5 Top Gene-Editing Stocks for 2019 Motley Fool
Mar-06-19 04:01PM  Sangamo Therapeutics Announces Participation At Upcoming Investor Conferences PR Newswire
Mar-04-19 07:46AM  Why Sangamo Therapeutics Lost 22.9% of Its Value in February Motley Fool
Feb-28-19 04:01PM  Sangamo Therapeutics Reports Fourth Quarter And Full Year 2018 Financial Results PR Newswire
Feb-21-19 04:01PM  Sangamo Therapeutics Announces Fourth Quarter and Full Year 2018 Conference Call and Webcast PR Newswire
10:31AM  Analysts Estimate Sangamo Therapeutics (SGMO) to Report a Decline in Earnings: What to Look Out for Zacks
09:47AM  2 Frustrating Flops, Plus Welcome to the Wrinkle Wars Motley Fool
07:55AM  Investor Expectations to Drive Momentum within Sangamo Therapeutics, AVEO Pharmaceuticals, Everbridge, Huntington Ingalls Industries, Woodward, and SAP SE Discovering Underlying Factors of Influence GlobeNewswire
Feb-20-19 07:30AM  Sangamo Announces FDA Acceptance of IND Application for ST-920 Gene Therapy Candidate for Fabry Disease PR Newswire
Feb-19-19 10:07AM  What's in Store for Sangamo (SGMO) This Earnings Season? Zacks
Feb-14-19 12:01PM  Is Moderna a Buy? Motley Fool
Feb-12-19 08:30AM  Biotech Stocks Rising ACCESSWIRE +7.57%
Feb-09-19 10:03AM  Should Sangamo's Failure Make CRISPR Investors Nervous? Motley Fool
08:16AM  Is Sangamo's Gene-Editing Approach a Bust? Motley Fool
Feb-08-19 09:17AM  The Daily Biotech Pulse: Big Miss For Seattle Genetics; Hematology Conference Presentations; Gossamer Bio, Harpoon IPOs Benzinga -7.10%
Feb-07-19 05:44PM  Why this East Bay biotech company shed half its value American City Business Journals -30.87%
04:00PM  Why Sangamo Therapeutics Crashed Today Motley Fool
01:43PM  Sangamo Fails To Impress Investors With Genome Editing Studies Benzinga
12:07PM  Sangamo Sinks Most in a Decade as Gene-Editing Study Fizzles Bloomberg
12:06PM  Tests suggest scientists achieved 1st 'in body' gene editing Associated Press
11:00AM  Sangamo Announces Interim Results Of Phase 1/2 EMPOWERS Study Evaluating SB-318 Zinc Finger Nuclease (ZFN) In Vivo Genome Editing Demonstrating Increased Leukocyte IDUA Activity In Patients With MPS I PR Newswire
11:00AM  Sangamo Announces Interim Results Of Phase 1/2 CHAMPIONS Study Showing Preliminary Evidence Of In Vivo Genome Editing In Patients With MPS II Treated With SB-913 PR Newswire
08:08AM  The Daily Biotech Pulse: Galapagos-Evotec Forge Fibrosis Partnership, Sanofi Earnings, Alector To Debut Benzinga
Feb-01-19 08:30AM  Sangamo Therapeutics To Host Conference Call To Review Interim Results From Phase 1/2 CHAMPIONS And EMPOWERS Studies For MPS II And MPS I PR Newswire +6.76%
Jan-29-19 07:45AM  Investor Expectations to Drive Momentum within Dollar General, Zayo Group, Cabot Oil & Gas, Sangamo Therapeutics, BioTelemetry, and Dean Foods Discovering Underlying Factors of Influence GlobeNewswire
Jan-24-19 09:35AM  Is Sangamo Therapeutics, Inc.s (NASDAQ:SGMO) CEO Salary Justified? Simply Wall St.
Jan-22-19 04:05PM  Sangamo Therapeutics Appoints Adrian Woolfson, BM., B.Ch., Ph.D., As Executive Vice President Of Research And Development PR Newswire
Jan-18-19 02:10PM  Here's How I Would Handle Speculative Sangamo Therapeutics TheStreet.com
07:43AM  Jim Cramer Advises His Viewers On Brink's, Medtronic And More Benzinga
Jan-17-19 06:48PM  Cramer's lightning round: 'I'm not endorsing' Fiat Chrysler's stock anymore CNBC
Jan-11-19 05:00AM  Top Picks 2019- Sangamo Therapeutics SGMO MoneyShow
Jan-08-19 09:15AM  Portfolios Making Up For Lost Time Zacks
Jan-04-19 08:00AM  Sangamo Therapeutics To Present at the 37th Annual J.P. Morgan Healthcare Conference PR Newswire +8.06%
08:00AM  Sangamo Announces Upcoming Clinical Data Presentations At WORLDSymposium 2019 PR Newswire
Dec-28-18 10:29AM  Biotech markets could be very promising in 2019 Yahoo Finance Video
Dec-20-18 05:59PM  Gilead Partners with Scholar Rock for Fibrotic Disease Drugs Zacks
Dec-17-18 08:00AM  Sangamo Announces Treatment Of First Patient In Phase 1/2 Clinical Trial Of In Vivo Genome Editing Therapy For Hemophilia B PR Newswire
Dec-11-18 03:55PM  Gilead Sciences (GILD) Appoints Daniel O'Day as New CEO Zacks
Dec-05-18 04:23PM  Gilead's (GILD) Harvoni and Descovy Get Approval in China Zacks
Dec-04-18 03:58PM  Gilead (GILD) Announces Data on CAR T Therapy Candidate Zacks -7.90%
09:23AM  Is Sangamo Therapeutics Inc (NASDAQ:SGMO) A Financially Sound Company? Simply Wall St.
Dec-03-18 07:00AM  Sangamo Announces Completion Of TxCell Acquisition PR Newswire
Dec-02-18 09:02AM  Better Buy: Editas Medicine vs. Sangamo Therapeutics Motley Fool
Nov-28-18 08:45AM  Report: Developing Opportunities within Costco Wholesale, Pepsico, Northern Oil and Gas, Codexis, Sangamo Therapeutics, and BRF S.A. Future Expectations, Projections Moving into 2018 GlobeNewswire
Nov-26-18 08:25AM  Gilead's HIV Franchise, CAR T Therapy Likely to Propel Growth Zacks
Nov-20-18 04:02PM  Gilead's Vemlidy Gets Approval in China for HBV Infection Zacks
Nov-18-18 04:51PM  Better Buy: CRISPR Therapeutics AG vs. Sangamo Therapeutics Inc. Motley Fool
10:31AM  Cutting-edge biotech Sangamo stock dives 12% after JPMorgan cites growing skepticism in downgrade MarketWatch
Nov-15-18 09:44AM  Sangamo's Shares Drop on Rating Downgrade, Pipeline Woes Zacks +8.94%
Nov-14-18 05:54PM  Here's Why Sangamo Therapeutics Lost 12% Today Motley Fool -11.94%
08:19AM  Sangamo stock drops after J.P. Morgan downgrade MarketWatch
Sangamo Therapeutics, Inc. focuses on translating science into genomic medicines that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The company's zinc finger proteins (ZFPs) could be engineered to make zinc finger nucleases (ZFNs), proteins that could be used to modify DNA sequences by adding or knocking out specific genes or genome editing; and ZFP transcription factors (ZFP TFs) proteins that can be used to increase or decrease gene expression or gene regulation. Its therapeutic products which are in Phase I/II clinical trial include SB-525 for the treatment of hemophilia A; SB-FIX for the treatment of hemophilia B; ST-400 for the treatment of beta-thalassemia; and SB-318 for the treatment of Mucopolysaccharidosis Type I and SB-913 for the treatment of Mucopolysaccharidosis Type II, which are lysosomal storage disorders (LSDs). The company also develops ST-920, a gene therapy for fabry disease. It has collaboration and license agreements with Kite Pharma, Inc., Pfizer Inc., Bioverativ Inc., and Shire International GmbH, as well as license partnerships with Dow AgroSciences LLC, Sigma-Aldrich Corporation, Genentech, Inc., Open Monoclonal Technology, Inc., F. Hoffmann-La Roche Ltd, and Hoffmann-La Roche Inc. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was founded in 1995 and is headquartered in Richmond, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Yi KathyEVP & Chief Financial OfficerMay 15Option Exercise4.555,00022,75030,512May 17 05:41 PM
Yi KathyEVP & Chief Financial OfficerMay 15Sale10.005,00050,00025,512May 17 05:41 PM
Yi KathyEVP & Chief Financial OfficerApr 15Option Exercise4.555,00022,75030,512Apr 16 07:27 PM
Yi KathyEVP & Chief Financial OfficerApr 15Sale12.115,00060,55025,512Apr 16 07:27 PM
Yi KathyEVP & Chief Financial OfficerMar 15Option Exercise4.555,00022,75030,512Mar 18 07:35 PM
Yi KathyEVP & Chief Financial OfficerMar 15Sale10.005,00050,00025,512Mar 18 07:35 PM
Yi KathyEVP & Chief Financial OfficerMar 01Option Exercise4.555,00022,75030,512Mar 05 08:21 PM
Yi KathyEVP & Chief Financial OfficerMar 01Sale10.005,00050,00025,512Mar 05 08:21 PM
Yi KathySVP & Chief Financial OfficerJan 15Option Exercise4.555,00022,75012,250Jan 16 04:08 PM
Yi KathySVP & Chief Financial OfficerJan 15Sale11.045,00055,2007,250Jan 16 04:08 PM
Conner Edward R.Sr. VP & Chief Medical OfficerJan 07Option Exercise3.205,00016,00017,125Jan 08 05:38 PM
Conner Edward R.Sr. VP & Chief Medical OfficerJan 07Sale12.335,00061,63112,125Jan 08 05:38 PM
Yi KathySVP & Chief Financial OfficerDec 17Option Exercise4.555,00022,75012,250Dec 18 05:35 PM
Yi KathySVP & Chief Financial OfficerDec 17Sale11.445,00057,2007,250Dec 18 05:35 PM
Conner Edward R.Sr. VP & Chief Medical OfficerDec 06Option Exercise3.205,00016,00017,125Dec 07 07:46 PM
Conner Edward R.Sr. VP & Chief Medical OfficerDec 06Sale11.495,00057,43312,125Dec 07 07:46 PM
Yi KathySVP & Chief Financial OfficerNov 15Option Exercise4.555,00022,75012,250Nov 16 05:16 PM
Yi KathySVP & Chief Financial OfficerNov 15Sale10.005,00050,0007,250Nov 16 05:16 PM
PARKER H STEWARTDirectorNov 14Buy9.002,00018,0027,500Nov 15 07:08 PM
Conner Edward R.Sr. VP & Chief Medical OfficerNov 06Option Exercise3.205,00016,00017,125Nov 07 05:41 PM
Conner Edward R.Sr. VP & Chief Medical OfficerNov 06Sale13.735,00068,65012,125Nov 07 05:41 PM
Yi KathySVP & Chief Financial OfficerOct 15Option Exercise4.555,00022,75012,250Oct 16 07:25 PM
Yi KathySVP & Chief Financial OfficerOct 15Sale13.975,00069,8507,250Oct 16 07:25 PM
Conner Edward R.Sr. VP & Chief Medical OfficerOct 08Option Exercise3.205,00016,00015,125Oct 09 05:40 PM
Conner Edward R.Sr. VP & Chief Medical OfficerOct 08Sale14.555,00072,77410,125Oct 09 05:40 PM
Yi KathySVP & Chief Financial OfficerSep 17Option Exercise4.555,00022,75012,250Sep 18 05:06 PM
Yi KathySVP & Chief Financial OfficerSep 17Sale14.665,00073,2857,250Sep 18 05:06 PM
PARKER H STEWARTDirectorSep 07Buy13.522,00027,0405,500Sep 07 05:45 PM
JEFFS ROGERDirectorSep 07Buy13.567,408100,4879,908Sep 07 07:18 PM
Conner Edward R.Sr. VP & Chief Medical OfficerSep 06Option Exercise3.205,00016,00015,125Sep 07 04:39 PM
Conner Edward R.Sr. VP & Chief Medical OfficerSep 06Sale14.175,00070,84510,125Sep 07 04:39 PM
Yi KathySVP & Chief Financial OfficerAug 16Option Exercise4.555,00022,75012,250Aug 17 04:17 PM
Yi KathySVP & Chief Financial OfficerAug 16Sale15.395,00076,9527,250Aug 17 04:17 PM
Conner Edward R.Sr. VP & Chief Medical OfficerAug 06Option Exercise3.205,00016,00015,125Aug 07 07:28 PM
Conner Edward R.Sr. VP & Chief Medical OfficerAug 06Sale13.455,00067,25010,125Aug 07 07:28 PM
Yi KathySVP & Chief Financial OfficerJul 16Option Exercise4.555,00022,75012,250Jul 17 04:16 PM
Yi KathySVP & Chief Financial OfficerJul 16Sale14.775,00073,8607,250Jul 17 04:16 PM
Conner Edward R.Sr. VP & Chief Medical OfficerJul 06Option Exercise3.205,00016,00015,125Jul 09 06:58 PM
Conner Edward R.Sr. VP & Chief Medical OfficerJul 06Sale15.805,00078,97510,125Jul 09 06:58 PM
open in yahoo | open in reuters | open in google